NovoCure (NASDAQ:NVCR) Trading 6.8% Higher - Should You Buy?

Key Points

• Shares jumped 6.8% after Q1 revenue of $174.1M (+12.3% Y/Y) beat estimates and management raised its FY‑2026 sales guidance to $690M–$710M, fueling investor optimism.
• Profitability remains a concern despite the top‑line beat: Q1 GAAP EPS missed at ($0.62) versus ($0.51) expected, with a negative net margin (~20.8%) and negative ROE, and analysts still model continued FY losses.
• Analyst views are mixed (average rating "Hold" and target ~$26.93) while insiders have sold shares recently and institutional ownership is high (~84.6%), signaling continued scrutiny despite the rally.

NovoCure Limited (NASDAQ:NVCR - Get Free Report)'s stock price rose 6.8% during mid-day trading on Friday . The company traded as high as $16.05 and last traded at $16.2460. Approximately 252,560 shares traded hands during trading, a decline of 86% from the average daily volume of 1,776,256 shares. The stock had previously closed at $15.21.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q1 revenue beat and management raised FY‑26 sales outlook — Q1 revenue came in at about $174.1M (roughly 12.3% Y/Y growth) and NovoCure boosted its FY‑2026 revenue guidance to $690M–$710M, which sits around or above consensus and drove optimism. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
• Positive Sentiment: Market commentary highlights the stock rally tied to the revenue beat and outlook bump — several investor writeups frame the news as a catalyst for a breakout given stronger-than-expected sales trends. Why NovoCure Limited’s (NVCR) Stock Is Up 19.53%
• Neutral Sentiment: Management commentary and the earnings slide deck provide more color on demand, regional performance and product cadence; investors will watch subsequent quarterly cadence vs. the raised sales range. NVCR Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Detailed Q1 snapshot coverage (transcript/summary) is available for investors wanting line‑by‑line trends by geography and product; these details will inform whether upside is sustainable. NovoCure: Q1 Earnings Snapshot
• Negative Sentiment: EPS missed and loss widened — Q1 GAAP EPS was a ($0.62) loss versus consensus around ($0.51), and profitability metrics (negative net margin, negative ROE) remain a concern. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Analyst profitability outlook still negative — street models expect continued FY losses, so upside depends on whether revenue growth converts to margin improvement over time. NovoCure (NVCR) Q1 2026 Earnings Transcript

Analyst Upgrades and Downgrades

NVCR has been the subject of a number of research reports. Wedbush reiterated a "neutral" rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, April 16th. Evercore reiterated an "outperform" rating on shares of NovoCure in a report on Friday. Weiss Ratings restated a "sell (e+)" rating on shares of NovoCure in a report on Tuesday, April 21st. Finally, HC Wainwright upped their price target on NovoCure from $47.00 to $49.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $26.93.

NovoCure Stock Performance

The company has a market capitalization of $1.90 billion, a PE ratio of -13.49 and a beta of 0.82. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.71 and a current ratio of 2.90. The company has a 50 day moving average price of $12.11 and a 200 day moving average price of $12.45.

NovoCure (NASDAQ:NVCR - Get Free Report) last released its earnings results on Thursday, April 30th. The medical equipment provider reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The business had revenue of $174.06 million for the quarter, compared to analysts' expectations of $167.77 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The business's quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) earnings per share. Equities analysts forecast that NovoCure Limited will post -1.51 EPS for the current year.

Insider Buying and Selling at NovoCure

In related news, CEO Frank X. Leonard sold 5,607 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $74,629.17. Following the sale, the chief executive officer directly owned 493,793 shares of the company's stock, valued at approximately $6,572,384.83. This represents a 1.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman William F. Doyle sold 71,887 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the sale, the chairman directly owned 328,397 shares in the company, valued at approximately $4,262,593.06. This represents a 17.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 140,041 shares of company stock worth $1,860,116. 5.52% of the stock is owned by insiders.

Institutional Investors Weigh In On NovoCure

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP raised its position in shares of NovoCure by 163.6% during the 3rd quarter. Quantbot Technologies LP now owns 195,515 shares of the medical equipment provider's stock valued at $2,526,000 after acquiring an additional 121,354 shares in the last quarter. Algert Global LLC raised its position in shares of NovoCure by 372.2% during the 3rd quarter. Algert Global LLC now owns 682,858 shares of the medical equipment provider's stock valued at $8,823,000 after acquiring an additional 538,235 shares in the last quarter. Tudor Investment Corp ET AL increased its position in NovoCure by 140.6% in the third quarter. Tudor Investment Corp ET AL now owns 606,070 shares of the medical equipment provider's stock worth $7,830,000 after buying an additional 354,216 shares during the period. JPMorgan Chase & Co. increased its position in NovoCure by 104.2% in the third quarter. JPMorgan Chase & Co. now owns 282,184 shares of the medical equipment provider's stock worth $3,646,000 after buying an additional 144,024 shares during the period. Finally, American Century Companies Inc. increased its position in NovoCure by 18.3% in the third quarter. American Century Companies Inc. now owns 1,218,807 shares of the medical equipment provider's stock worth $15,747,000 after buying an additional 188,933 shares during the period. 84.61% of the stock is owned by institutional investors and hedge funds.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.